Ovid Therapeutics Inc.: 5%+ holders

As of November 9, 2026, 8 holders' latest Schedule 13D or 13G filings report owning 5% or more of Ovid Therapeutics Inc. The largest reported stake is Takeda Pharmaceutical Company Limited's, at 12.3%. 24 filings are on record since July 9, 2025 (Schedule 13G/A, December 9, 2025).

Eventide Asset Management, LLC also filed stake reports on 9 other companies ↓

Sell to companies like Ovid Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 19,549,271 · Sole dispositive: 0 · Shared dispositive: 19,549,271 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Eventide Asset Management, LLC · Sole voting: 11,812,241 · Shared voting: 0 · Sole dispositive: 11,812,241 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: ADAR1 Capital Management, LLC · Sole voting: 0 · Shared voting: 9,559,979 · Sole dispositive: 0 · Shared dispositive: 9,559,979 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Balyasny Asset Management L.P. · Sole voting: 9,313,341 · Shared voting: 0 · Sole dispositive: 9,313,341 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-13 · Reporting person: Affinity Asset Advisors, LLC · Sole voting: 15,143,728 · Shared voting: 0 · Sole dispositive: 15,143,728 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-13

Ovid Therapeutics Inc. has 24 Schedule 13D or 13G filings on record since 2025-07-09. 8 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Ovid Therapeutics Inc. and the warning signs.

See Ovid Therapeutics Inc.'s free Snapshot Watch Ovid Therapeutics Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Ovid Therapeutics Inc. and the records around it.

Ovid Therapeutics Inc. elsewhere on the record

• Leadership changes Jul 2026
• Who owns it

Companies that share a holder

• Eventide Asset Management, LLC also filed stake reports on 9 other companies: Immix Biopharma, Inc. (Aug 2026), Beta Bionics, Inc. (May 2026), COLLEGIUM PHARMACEUTICAL, INC (May 2026)
• Affinity Asset Advisors, LLC also filed stake reports on 13 other companies: Amanat Acquisition Corp. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Equillium Inc. (Aug 2026)
• Federated Hermes, Inc. also filed stake reports on 13 other companies: EyePoint (Nov 2026), Arcturus Therapeutics Holdings Inc. (Oct 2026), Forte Biosciences, Inc. (Sep 2026)

Want the whole picture on Ovid Therapeutics Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Ovid Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Ovid Therapeutics Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   26 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Ovid Therapeutics Inc. by CUSIP 690469101 and gives its principal executive office as 441 Ninth Avenue, 14th Floor, New York, NY 10001 (SCHEDULE 13G/A, 2026-08-14).

What the percentages are based on

Due to the Beneficial Ownership Blocker listed in the Warrants, each Reporting Person's beneficial ownership percentage was 9.99% as of June 30, 2026.RA Capital Management, L.P., SCHEDULE 13G/A, 2026-08-14

Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 4.99% of the Shares, based on 186,640,102 Shares outstanding as of May 8, 2026, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026.Balyasny Asset Management L.P., SCHEDULE 13G/A, 2026-08-14

Timeline

Swipe the table sideways to see every column.

Questions about who owns Ovid Therapeutics Inc.

Who owns Ovid Therapeutics Inc.?

On this page, 8 holders' latest ownership filings report 5% or more of Ovid Therapeutics Inc.: Takeda Pharmaceutical Company Limited (12.3%, Schedule 13G/A, filed 2025-12-09), Janus Henderson Group Plc (9.99%, Schedule 13G, filed 2025-12-08), RA Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-08-14), Sirenia Capital Management LP (9.9%, Schedule 13G, filed 2026-05-15) and Affinity Asset Advisors, LLC (7.9%, Schedule 13G/A, filed 2026-08-13); 3 more are listed above.

Who are the largest shareholders of Ovid Therapeutics Inc.?

By the share each holder's latest filing reports, the largest holders of Ovid Therapeutics Inc. on this page are Takeda Pharmaceutical Company Limited (12.3%), Janus Henderson Group Plc (9.99%) and RA Capital Management, L.P. (9.9%).

When did Takeda Pharmaceutical Company Limited buy into Ovid Therapeutics Inc.?

The filings give report dates, not purchase dates. The earliest filing from Takeda Pharmaceutical Company Limited on this page is the Schedule 13G/A, filed 2025-12-09, reporting 12.3%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 24 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Ovid Therapeutics Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Ovid Therapeutics Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Ovid Therapeutics Inc. is mentioned again
• Find former Ovid Therapeutics Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes